Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

• Published in: Neurology Vol. 90; no. 3; pp. 126 - 135
• Main Authors: Petersen, Ronald C, Lopez, Oscar, Armstrong, Melissa J, Getchius, Thomas S.D, Ganguli, Mary, Gloss, David, Gronseth, Gary S, Marson, Daniel, Pringsheim, Tamara, Day, Gregory S, Sager, Mark, Stevens, James, Rae-Grant, Alexander
• Format: Journal Article
• Language: English
• Published: United States American Academy of Neurology 16-01-2018; Lippincott Williams & Wilkins
• Subjects: Cognitive Dysfunction - diagnosis; Cognitive Dysfunction - epidemiology; Cognitive Dysfunction - therapy; Delphi Technique; Humans; Special
• ISSN: 0028-3878; 1526-632X
• DOI: 10.1212/WNL.0000000000004826

OBJECTIVETo update the 2001 American Academy of Neurology (AAN) guideline on mild cognitive impairment (MCI).
METHODSThe guideline panel systematically reviewed MCI prevalence, prognosis, and treatment articles according to AAN evidence classification criteria, and based recommendations on evidence and modified Delphi consensus.
RESULTSMCI prevalence was 6.7% for ages 60–64, 8.4% for 65–69, 10.1% for 70–74, 14.8% for 75–79, and 25.2% for 80–84. Cumulative dementia incidence was 14.9% in individuals with MCI older than age 65 years followed for 2 years. No high-quality evidence exists to support pharmacologic treatments for MCI. In patients with MCI, exercise training (6 months) is likely to improve cognitive measures and cognitive training may improve cognitive measures.
MAJOR RECOMMENDATIONSClinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).